Pluristem Therapeutics, a developer of placenta-based cell therapies, announced it has received approval from the Paul-Ehrlich-Institute (PEI), the medical regulatory body in Germany, to commence a Phase I/II study to assess the safety and efficacy of its treatment for the regeneration of injured gluteal musculature following total hip replacement. The Company’s patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. The company is headquartered in Haifa, Israel with offices the US.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Data Privacy Startup Raises $30M in Wartime
December 05, 2023

Israel Awards ‘World’s First’ License For Drone Flights
December 05, 2023

Israeli Firm Unveils ‘Strongest’ Radar Processor For AVs
December 04, 2023

New AI Platform Simulates Thousands Of Clinical Trials At Once
December 04, 2023
Facebook comments